American Journal of
Oral Medicine and Radiology

ISSN - 2394-7721

www.mcmed.us/journal/ajomr

Review Article

ADVANCES IN TOPICAL DRUG DELIVERY FOR ORAL MUCOSAL DISORDERS: A REVIEW OF CURRENT STRATEGIES

Dr. Dinesh Venkatesan D*

Private Practitioner, Chennai, India.

ABSTRACT

Topical drug delivery for oral mucosal disorders has gained considerable attention due to its potential to improve therapeutic outcomes while minimizing systemic side effects. Oral mucosal disorders, including oral ulcers, gingivitis, periodontitis, and mucositis, often require localized treatment to target the affected areas without affecting the rest of the body. Traditional oral medications and systemic treatments frequently fail to deliver drugs efficiently to the oral mucosa, leading to suboptimal therapeutic effects and increased risk of side effects. Advances in topical drug delivery systems have focused on overcoming these challenges by providing controlled, sustained, and targeted drug release directly at the site of action. Recent strategies, including the use of mucoadhesive formulations, nanoparticles, liposomes, hydrogels, and polymeric films, have shown promise in enhancing drug retention, improving drug absorption, and providing localized relief. Mucoadhesive systems, in particular, have the advantage of prolonging contact time with the mucosal surface, ensuring sustained drug release and better therapeutic efficacy. Furthermore, nanotechnology has introduced new possibilities for enhancing drug solubility, stability, and bioavailability in the oral cavity, allowing for more precise and effective treatments. This review explores the current strategies in topical drug delivery for oral mucosal disorders, highlighting the latest advancements, the mechanisms behind these innovations, and the clinical applications of these systems. The review also discusses the challenges faced in the development and clinical implementation of these systems, such as patient compliance, formulation stability, and the need for personalized treatments. By focusing on improving the targeted delivery of therapeutic agents, these advancements aim to improve the management of oral mucosal disorders and enhance the quality of life for affected individuals.

Keywords: - Pharmacokinetics, oral medications, absorption, distribution, metabolism, excretion.

Access this article online		
Home page: **http://www.mcmed.us/journal/ajomr**		**Quick Response code**
Received:07.02.2026	**Revised**:10.03.2026	**Accepted**:14.04.2026

INTRODUCTION

Oral mucosal disorders are a common and challenging clinical issue, with conditions like oral ulcers, gingivitis, periodontitis, and mucositis requiring effective treatment to manage symptoms and prevent further complications. Traditional treatment approaches, such as systemic therapies or simple oral formulations, often fail to address the unique needs of the oral mucosa, resulting in suboptimal therapeutic outcomes. This has spurred significant interest in topical drug delivery systems specifically designed for oral mucosal disorders,

Corresponding Author
Dr. Dinesh Venkatesa D

which aim to provide localized, targeted, and sustained drug release directly at the site of action. The oral mucosa presents unique challenges for drug delivery, including a relatively high turnover rate of cells, constant exposure to saliva, and variability in drug permeability, which complicates the effectiveness of treatments. Topical drug delivery systems have been developed to overcome these challenges by ensuring that the drug remains in contact with the mucosal surface for prolonged periods, thereby improving absorption and therapeutic efficacy.[1] One of the most promising strategies involves the use of mucoadhesive formulations, which adhere to the mucosal surface and offer sustained release of active ingredients. These systems not only enhance the retention of the drug at the site of infection or inflammation but also improve patient compliance by reducing the frequency of dosing. In addition, advancements in nanotechnology have led to the development of nanoparticles and liposomes that encapsulate drugs, improving their solubility, stability, and bioavailability. These drug carriers can also target specific tissues within the oral cavity, ensuring that drugs are delivered precisely where they are needed, such as in periodontal pockets or mucosal lesions. Hydrogels and polymeric films are also gaining attention for their ability to provide controlled release and improve drug retention while protecting the affected tissue from external factors. The combination of these strategies has the potential to significantly enhance the treatment of oral mucosal disorders, offering more effective, localized, and patient-friendly alternatives to traditional oral and systemic therapies. However, despite the promising results, there are still challenges in terms of formulation stability, patient compliance, and the need for individualized treatment approaches, which require further research and development[2]. This review will delve into the current strategies for topical drug delivery in oral mucosal disorders, exploring their mechanisms, clinical applications, and future directions for improving therapeutic outcomes in this specialized area of oral health.

The Challenge of Oral Mucosal Disorders and the Need for Effective Drug Delivery

Oral mucosal disorders, including conditions such as oral ulcers, gingivitis, periodontitis, and mucositis, present significant challenges for both patients and healthcare providers. These disorders often cause discomfort, pain, and functional impairments, significantly affecting a patient's quality of life. Despite the prevalence of these conditions, effective treatment remains difficult due to the limitations of conventional drug delivery methods. Traditional oral medications and systemic therapies may not provide adequate localized action, as they fail to achieve high enough concentrations in the affected oral mucosal tissues, leading to suboptimal therapeutic outcomes. Moreover, the constant exposure of the oral cavity to saliva and the relatively high turnover rate of the mucosal cells complicate the retention and absorption of therapeutic agents[3]. As a result, oral mucosal disorders often require treatments that are not only effective but also capable of delivering drugs directly to the affected areas in a sustained and localized manner. Current strategies for treating these conditions often involve either topical applications or systemic therapies, which come with their own limitations. While topical therapies provide localized relief, they are often rapidly washed away by saliva, reducing their effectiveness. Systemic treatments, on the other hand, may result in unwanted side effects due to their lack of specificity. To address these challenges, innovative drug delivery systems are needed that can overcome the physiological barriers of the oral cavity, such as the mucosal barrier, saliva production, and the rapid turnover of epithelial cells. Advanced drug delivery technologies, such as mucoadhesive systems, nanoparticles, and controlled-release formulations, have the potential to provide sustained, localized drug release, improving therapeutic outcomes for patients with oral mucosal disorders. These systems not only enhance drug retention at the site of action but also reduce the need for frequent dosing, improving patient compliance[4]. Therefore, the development of more efficient and effective drug delivery systems is critical in the management of oral mucosal disorders, ultimately enhancing both the safety and effectiveness of treatment options available to patients.

Physiological Barriers in Oral Mucosal Drug Delivery

The oral mucosa presents several physiological barriers that complicate the effective delivery of therapeutic agents. These barriers include the anatomical structure of the mucosa, the rapid turnover of epithelial cells, constant salivation, and the high permeability of the oral tissues, all of which can hinder drug absorption and retention. The mucosal surface of the oral cavity is composed of a stratified squamous epithelium, which provides a protective barrier against external substances. However, this barrier, while essential for defense, limits the penetration of drugs into the underlying tissues. The high turnover rate of the oral mucosa—where cells are continually replaced—also reduces

the duration of drug retention on the mucosal surface, which is a significant challenge for sustained drug release. Furthermore, the presence of saliva in the oral cavity poses another obstacle to drug delivery. Saliva continually flushes the oral cavity, which can rapidly dilute and wash away topically applied drugs, reducing their efficacy[5]. Additionally, the presence of enzymes in saliva, such as amylase, can lead to the premature degradation of some drugs, further complicating drug delivery. Another significant challenge is the variability in drug absorption across different regions of the oral cavity. The permeability of the oral mucosa varies between different regions, such as the buccal mucosa, sublingual area, and the gingiva, which may require different delivery strategies for optimal absorption. Additionally, the high vascularization of the oral mucosa facilitates quick distribution of drugs, but this also means that drugs are rapidly cleared from the system, reducing their residence time at the target site. For drugs that require prolonged exposure to the affected tissue, these physiological barriers must be overcome. Consequently, new drug delivery systems must be designed to enhance drug stability, retention, and absorption, overcoming the natural challenges posed by the oral mucosa to provide targeted and sustained therapeutic effects.

Structure of the Oral Mucosa: Implications for Drug Absorption

The structure of the oral mucosa plays a pivotal role in determining the absorption characteristics of drugs administered via the oral cavity. The oral mucosa is composed of several layers, with the outermost being the keratinized epithelium, followed by the non-keratinized mucosal layer and the underlying connective tissue. The epithelium forms a barrier that protects the underlying tissues from mechanical damage and microbial invasion. However, this barrier also limits the absorption of many drugs, particularly large molecules. The permeability of the oral mucosa varies across different regions, with the sublingual mucosa being more permeable compared to the buccal mucosa or the gingiva. The sublingual area, with its thin, non-keratinized epithelium and rich blood supply, allows for rapid absorption of drugs into the systemic circulation, making it an ideal site for delivering medications that require fast onset of action, such as nitroglycerin or fentanyl. In contrast, the buccal mucosa, while also capable of drug absorption, is less permeable and requires formulations that can enhance retention and penetration, such as mucoadhesive systems or nanoparticles[6]. The permeability of the mucosa is further influenced by factors such as age, hydration, and disease state, with conditions like inflammation or mucosal damage altering drug absorption. Additionally, the saliva present in the oral cavity plays a significant role in drug absorption. Saliva not only helps to dissolve drugs but also facilitates their diffusion across the mucosal barrier. However, the constant flow of saliva can also dilute the drug concentration and wash away formulations, leading to reduced drug retention and absorption. The presence of enzymes in saliva can also contribute to the degradation of drugs, further complicating oral drug delivery. These structural and physiological characteristics of the oral mucosa must be carefully considered when designing drug delivery systems for oral use. To enhance drug absorption, innovative approaches such as controlled-release formulations, mucoadhesive systems, and nanoparticles are being developed to improve drug retention and ensure sustained therapeutic levels at the site of action.

Nanoparticles and Nanocarriers for Targeted Delivery

Nanoparticles and nanocarriers have emerged as promising tools for targeted drug delivery in the treatment of oral mucosal disorders, offering significant advantages over conventional drug delivery systems. The small size of nanoparticles, typically ranging from 1 to 1000 nanometers, enables them to penetrate biological barriers, such as the oral mucosa, more effectively than larger drug molecules. This enhanced permeability makes nanoparticles particularly useful for delivering drugs to localized sites in the oral cavity, such as the gingiva or periodontal pockets, where conventional therapies may fail to achieve adequate drug concentrations. Nanocarriers, including liposomes, solid lipid nanoparticles, and polymeric nanoparticles, can encapsulate a wide range of therapeutic agents, including both hydrophilic and hydrophobic drugs, protecting them from degradation and improving their stability and bioavailability. The surface of nanoparticles can also be modified with specific ligands or antibodies, enabling them to target specific cells or tissues in the oral cavity. This targeted approach improves the precision of drug delivery, reducing the risk of side effects and enhancing therapeutic efficacy[7]. In the case of oral mucosal disorders, such as periodontal disease or oral ulcers, nanoparticles can be used to deliver anti-inflammatory agents, antimicrobial drugs, or analgesics directly to the affected area, providing localized relief and accelerating the healing process. Additionally, the controlled release properties of nanoparticles allow for sustained drug delivery,

reducing the need for frequent dosing and improving patient compliance. Nanoparticles can also be engineered to release drugs in response to specific stimuli, such as changes in pH or temperature, further enhancing their targeting ability. Despite their promising potential, the clinical application of nanoparticles in oral drug delivery faces challenges, including issues related to stability, manufacturing, and regulatory approval. However, ongoing research in nanotechnology continues to push the boundaries of drug delivery, offering exciting possibilities for improving the treatment of oral mucosal disorders and other conditions.

Microneedle Systems and Their Potential in Oral Mucosal Drug Delivery

Microneedle systems represent a novel and highly promising approach for oral mucosal drug delivery, offering an effective means of bypassing the limitations posed by the mucosal barrier and achieving targeted, localized drug administration. Microneedles are small, typically ranging from 25 to 1000 microns in length, and are designed to create micro-sized channels in the oral mucosa, allowing for the enhanced delivery of drugs through these transient pores. Unlike conventional needles used for injection, microneedles are painless, minimally invasive, and can be easily applied to the oral cavity, making them an attractive option for patient-friendly drug delivery systems. The main advantage of microneedle systems in oral drug delivery is their ability to provide precise, controlled, and localized drug release at the target site, such as the gingiva or mucosal lesions, without the systemic exposure that is common with oral medications[8]. The small size of the microneedles enables them to penetrate the upper layers of the mucosa without causing significant pain or discomfort, ensuring a non-invasive alternative to traditional injection methods. Microneedles can be used to deliver a wide range of therapeutic agents, including vaccines, analgesics, anti-inflammatory drugs, and antimicrobial agents, directly to the mucosal tissues. This direct delivery to the site of action enhances the drug's bioavailability, improves therapeutic efficacy, and reduces the need for frequent dosing. Moreover, microneedles can be combined with other drug delivery systems, such as nanoparticles or liposomes, to further enhance drug stability, solubility, and release characteristics. The combination of microneedles with controlled-release formulations offers the potential for sustained drug delivery, improving patient compliance and reducing treatment frequency. Despite the promising potential of microneedles, challenges remain in their clinical implementation, including the development of materials that are both biocompatible and effective in drug release, as well as the need for regulatory approval. Nonetheless, microneedle systems hold significant potential for revolutionizing oral mucosal drug delivery and improving the management of oral disorders, offering a minimally invasive, patient-friendly, and efficient approach to drug therapy.

Hydrogels and Biodegradable Films for Controlled Release

Hydrogels and biodegradable films have emerged as innovative drug delivery systems in the treatment of oral mucosal disorders, providing controlled and sustained drug release while ensuring minimal systemic exposure and side effects. Hydrogels are three-dimensional, water-swollen polymeric networks that can encapsulate a wide variety of drugs, including hydrophilic and lipophilic molecules, and provide prolonged drug release by controlling the diffusion of the drug through the polymer matrix. The ability of hydrogels to absorb large amounts of water makes them particularly useful for maintaining hydration at the site of application, which is beneficial in the treatment of dry mouth or mucositis. In addition to their drug-delivery capabilities, hydrogels have been shown to enhance tissue healing and reduce inflammation, making them ideal for use in oral mucosal disorders such as periodontal disease, oral ulcers, and gingivitis. Biodegradable films, on the other hand, offer a more solid form of drug delivery that can adhere to the mucosal surface, providing sustained drug release over time. These films, often made from biocompatible and biodegradable polymers, are designed to degrade naturally in the body, eliminating the need for removal and reducing the risk of irritation or discomfort[9]. Both hydrogels and biodegradable films offer the advantage of mucoadhesion, which ensures that the drug remains in contact with the mucosal surface for an extended period, enhancing drug absorption and therapeutic efficacy. The controlled release provided by these systems also reduces the frequency of dosing, improving patient compliance. Moreover, both hydrogels and films can be customized to release drugs in response to specific stimuli, such as pH or temperature changes, allowing for targeted delivery and improved treatment outcomes. Despite their many advantages, challenges remain in the development of hydrogels and films, particularly in optimizing their stability, drug release profiles, and patient acceptance. However, these advanced drug delivery systems hold great promise in improving the management of oral mucosal disorders by providing sustained, localized, and effective treatment options.

Mechanisms of Mucoadhesion and Their Impact on Drug Delivery

Mucoadhesion is a critical property for oral drug delivery systems, particularly for those aimed at treating oral mucosal disorders. The mechanism of mucoadhesion involves the interaction between a drug delivery system and the mucosal surface, allowing the system to adhere to the mucosa for extended periods, thereby improving drug retention and absorption. This is achieved through both physical and chemical interactions, such as hydrogen bonding, van der Waals forces, and ionic interactions, between the drug delivery system and the mucosal surface. Mucoadhesive drug delivery systems, including gels, films, and patches, are designed to provide prolonged contact with the mucosal surface, enhancing drug release and ensuring that therapeutic concentrations are maintained at the site of action for longer periods. The mucoadhesion process is influenced by several factors, including the molecular structure of the polymer used in the formulation, the surface characteristics of the oral mucosa, and the environmental conditions, such as pH and salivation rates[10]. The more adhesive the system is to the mucosal surface, the longer the drug remains in contact with the target tissue, which is especially important for conditions that require sustained therapy, such as periodontal disease or oral ulcers. In addition, mucoadhesive formulations can help reduce the frequency of dosing by providing controlled drug release, improving patient compliance. Moreover, mucoadhesion can enhance the targeting of drugs to specific regions of the oral cavity, such as the gingiva or periodontal pockets, allowing for more localized and effective treatment. However, the development of mucoadhesive systems must balance adhesive strength with ease of removal, as excessive adhesion can lead to discomfort or difficulty in drug removal. The ability to tailor mucoadhesive formulations to different oral conditions and patient needs is crucial for improving the effectiveness and acceptability of oral mucosal drug therapies.

Strategies to Enhance Mucoadhesion and Prolong Drug Action

Enhancing mucoadhesion and prolonging drug action are key objectives in the development of drug delivery systems for oral mucosal disorders, ensuring that therapeutic agents remain in contact with the target tissue for extended periods and are released in a controlled manner. Several strategies have been developed to enhance the mucoadhesion of drug delivery systems, including the use of specific polymers and excipients that promote strong interactions with the mucosal surface. Polymers such as carbomers, hydroxypropyl methylcellulose (HPMC), chitosan, and polyacrylic acid have been extensively studied for their ability to form stable and adhesive networks with the mucosal layer, increasing the residence time of the drug at the site of action. These polymers interact with mucins on the mucosal surface through hydrogen bonds, electrostatic interactions, and van der Waals forces, which enhance adhesion. In addition to selecting the appropriate mucoadhesive materials, the formulation's physicochemical properties, such as viscosity, charge, and molecular weight, can be optimized to further improve adhesion and drug retention. Another approach is the development of composite systems that combine mucoadhesive polymers with other materials, such as nanoparticles or liposomes, to enhance drug stability, solubility, and absorption[11].

Nanoparticle-Based Targeting Approaches for Improved Drug Efficacy

Nanoparticle-based targeting approaches represent a significant advancement in drug delivery systems, offering the potential to improve drug efficacy in the treatment of oral mucosal disorders by enhancing the precision of drug delivery to specific tissues. Nanoparticles, due to their small size and large surface area, can be engineered to encapsulate a wide range of therapeutic agents, including hydrophilic and hydrophobic drugs, and deliver them directly to the target site in a controlled manner. One of the key advantages of nanoparticle-based drug delivery systems is their ability to target specific cells or tissues in the oral cavity. This can be achieved through surface modifications, such as the attachment of targeting ligands or antibodies, which recognize and bind to specific receptors on the surface of target cells. For example, nanoparticles can be functionalized to target inflamed or infected tissues in periodontal disease or to deliver drugs directly to mucosal lesions in oral ulcers. This targeted approach enhances the therapeutic efficacy of drugs by ensuring that they reach the affected area at the appropriate concentration while minimizing systemic exposure and reducing the risk of side effects[12]. Additionally, the small size of nanoparticles allows them to penetrate biological barriers, such as the oral mucosa, more effectively than larger drug molecules, improving drug absorption and bioavailability. Nanoparticles can also be designed to release drugs in response to specific stimuli, such as pH, temperature, or enzymatic activity, providing more precise control over the timing and location of drug release. This feature is particularly useful for

sustained or controlled release, ensuring that the drug remains at the site of action for an extended period. Despite the promising potential of nanoparticle-based targeting, challenges remain in their clinical application, including issues related to stability, production scalability, and regulatory approval. However, ongoing research in nanotechnology holds great promise for improving the treatment of oral mucosal disorders, providing more efficient, localized, and patient-friendly drug delivery options.

Biocompatibility and Safety Aspects of Oral Mucosal Drug Delivery Systems

The biocompatibility and safety of oral mucosal drug delivery systems are crucial factors in ensuring the successful development and clinical application of these systems. Given that these drug delivery systems are designed for prolonged contact with sensitive oral tissues, it is essential that the materials used in their formulation do not cause irritation, inflammation, or toxicity to the mucosal surface. Biocompatibility refers to the ability of a material to interact with the biological environment without causing harmful effects, and it is a critical consideration in the development of drug delivery systems for oral use. Common materials used in oral mucosal drug delivery systems include polymers, nanoparticles, hydrogels, and mucoadhesive materials, all of which must meet stringent biocompatibility criteria to ensure they do not induce adverse reactions. For example, polymers such as hydroxypropyl methylcellulose (HPMC), chitosan, and polyacrylic acid are often used due to their relatively low toxicity and ability to form stable drug-delivery matrices. However, it is important to assess the potential for these materials to cause localized irritation or allergic reactions in patients, especially for long-term use[13]. In addition to biocompatibility, the safety of oral mucosal drug delivery systems is influenced by their pharmacokinetics, including their ability to be absorbed, distributed, metabolized, and excreted without causing systemic toxicity. Drug release profiles must be carefully designed to prevent the accumulation of drugs at the application site, which could lead to side effects such as mucosal damage or systemic absorption. Nanoparticles and other advanced drug carriers also require thorough safety evaluations to ensure they do not induce cytotoxicity, genotoxicity, or other harmful effects on mucosal cells. Additionally, the safety of drug delivery systems must be assessed with respect to their interaction with saliva, as well as their potential to be swallowed, leading to unintended systemic exposure. Overall, ensuring biocompatibility and safety is fundamental for the successful application of oral mucosal drug delivery systems in clinical practice, requiring comprehensive testing and careful consideration of the materials used in these innovative formulations.

Integration of Digital Health Technologies in Mucosal Drug Delivery

The integration of digital health technologies into oral mucosal drug delivery systems represents an exciting frontier in personalized medicine, offering the potential to optimize drug administration, monitor treatment efficacy, and improve patient compliance. Digital health technologies, including mobile apps, wearable devices, and smart sensors, can be used to track and manage drug delivery in real-time, providing valuable feedback to both patients and healthcare providers. For example, smart drug delivery systems can be equipped with sensors that monitor the release of drugs from mucoadhesive films or hydrogels, allowing for precise control over the timing and dosage of the drug. This technology can ensure that the drug is delivered at the optimal rate for maximum efficacy, enhancing treatment outcomes for oral mucosal disorders such as periodontal disease, oral ulcers, and mucositis[14]. Mobile apps can also be used to track patient adherence to treatment regimens, sending reminders for medication use and providing educational resources about managing oral mucosal conditions. Furthermore, digital health technologies can assist in collecting data on patient responses to treatment, which can be analyzed to refine therapy and customize drug delivery strategies. In addition to improving drug delivery, digital health technologies enable continuous monitoring of patient health status, including symptoms, side effects, and treatment progress. This real-time monitoring allows for timely adjustments to therapy, preventing complications and ensuring better management of chronic oral conditions. As digital health technologies continue to evolve, their integration with drug delivery systems will provide new opportunities for personalized, efficient, and patient-centric care in the treatment of oral mucosal disorders. By combining the precision of drug delivery systems with the real-time data provided by digital health tools, the future of oral mucosal drug therapy looks promising, offering improved therapeutic outcomes and enhanced patient satisfaction.

Potential of Biologic and Gene-Based Therapies for Oral Mucosal Disorders

Biologic and gene-based therapies hold great promise for the treatment of oral mucosal disorders,

offering innovative approaches to addressing the underlying causes of these conditions. Biologic therapies, including monoclonal antibodies, cytokines, and growth factors, target specific molecular pathways involved in inflammation, tissue regeneration, and immune responses, providing highly targeted treatment with fewer systemic side effects compared to traditional therapies. For example, biologics targeting pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) have shown efficacy in treating conditions like periodontitis and oral mucositis, where chronic inflammation plays a central role in disease progression. These therapies can provide significant relief by modulating the immune response, reducing inflammation, and promoting tissue healing. Gene-based therapies, on the other hand, offer the potential to directly modify the genetic material within oral mucosal cells to correct underlying dysfunctions. For instance, gene editing techniques such as CRISPR-Cas9 could be used to correct genetic defects that contribute to chronic oral conditions or to deliver therapeutic genes that promote tissue regeneration and healing. Gene-based therapies could also be used to enhance the expression of protective proteins or growth factors in the oral mucosa, promoting faster recovery from injuries, ulcers, or other mucosal damage[15]. The integration of gene therapy with advanced drug delivery systems, such as nanoparticles or viral vectors, enables targeted delivery of genetic material to the affected tissues, ensuring precise and effective treatment. While these approaches hold great promise, there are still challenges related to safety, delivery efficiency, and long-term effects, which require further research and clinical validation. Nonetheless, the potential of biologic and gene-based therapies to revolutionize the treatment of oral mucosal disorders is significant, offering more personalized, effective, and targeted therapeutic options for patients with chronic or refractory conditions.

CONCLUSION

The advancements in topical drug delivery systems for oral mucosal disorders represent a significant step forward in the treatment of various oral health conditions, such as periodontal disease, oral ulcers, gingivitis, and mucositis. Traditional oral drug administration methods often fail to provide adequate localized treatment, and systemic therapies can result in unwanted side effects due to drug distribution throughout the body. The innovative strategies in topical drug delivery for oral mucosal disorders aim to overcome these limitations by focusing on providing sustained, localized, and controlled release of therapeutic agents directly to the affected areas. Mucoadhesive formulations, such as gels, films, and patches, have shown remarkable potential by adhering to the mucosal surface, ensuring that drugs remain in contact with the target site for extended periods, thus enhancing drug absorption and therapeutic efficacy. These systems are particularly beneficial in managing chronic conditions that require continuous treatment, such as periodontal disease and oral mucositis, as they provide more consistent drug release while minimizing systemic exposure. Furthermore, the integration of nanotechnology into drug delivery systems has opened new possibilities for improving drug solubility, stability, and bioavailability, ensuring that drugs are effectively delivered to deeper tissues, such as the gingiva or periodontal pockets, which are often difficult to reach with conventional therapies. Nanocarriers, including liposomes, nanoparticles, and dendrimers, can encapsulate a broad range of therapeutic agents, providing enhanced drug retention and protection from degradation, thereby improving the overall treatment outcome. Additionally, the use of hydrogels and biodegradable films offers promising controlled release systems, providing localized drug delivery while promoting tissue regeneration and reducing inflammation, which is critical in the management of oral mucosal disorders. These drug delivery systems can also be designed to respond to environmental stimuli, such as changes in pH or temperature, allowing for more targeted and efficient drug release.

REFERENCES

1. Sharma, D., & Garg, R. (2020). Recent developments and potential of mucoadhesive buccal drug delivery system for oro-mucosal disorders. *CDENT, 2*, 12–28.
2. Phukan, M., Gogoi, B., Parasar, A., & Pegu, F. (2024). Recent developments in the mucoadhesive drug delivery system domain. In *Recent Developments in the Mucoadhesive Drug Delivery System Domain* (pp. 104–133). Iterative International Publishers Selfypage Developers Pvt. Ltd.
3. Pan, Z., Zhang, X., Xie, W., Cui, J., Wang, Y., Zhang, B., et al. (2024). Revisited and innovative perspectives of oral ulcer: From biological specificity to local treatment. *Frontiers in Bioengineering and Biotechnology, 12*, 1335377.

4. Golshani, S., Vatanara, A., & Amin, M. (2022). Recent advances in oral mucoadhesive drug delivery. *Journal of Pharmacy & Pharmaceutical Sciences, 25*, 201–217.
5. Alharbi, N., Aljohani, I., Rashdi, A., Shehri, H., Nashib, A., Madkhali, R., et al. (2024). Exploring recent progress in oral drug delivery systems.
6. Mazzinelli, E., Favuzzi, I., Arcovito, A., Castagnola, R., Fratocchi, G., Mordente, A., et al. (2023). Oral mucosa models to evaluate drug permeability. *Pharmaceutics, 15*, 1559.
7. Abdellatif, M. M., Ahmed, S. M., El-Nabarawi, M. A., & Teaima, M. (2023). Nano-delivery systems for enhancing oral bioavailability of drugs. *International Journal of Applied Pharmaceutics*, 13–19.
8. Panda, A., Matadh, V. A., Suresh, S., Shivakumar, H. N., & Murthy, S. N. (2021). Non-dermal applications of microneedle drug delivery systems. *Drug Delivery and Translational Research, 12*, 67–78.
9. Dongwen, L., Dapeng, M., Jiazhi, Y., & Xiaoguang, L. (2025). Hydrogels in oral disease management: A review of innovations in drug delivery and tissue regeneration. *Medical Science Monitor, 31*, e946122.
10. Rajnish, S., Nilesh, B., & Shukla, S. (2022). Review on mucoadhesive drug delivery systems. *IRJMETS*.
11. Tüküç, T. B., Alarçin, E., & Bal Öztürk, A. (2025). Recent progress in the development of localized drug delivery systems for oral mucosal disorders using mucoadhesive patches. *Journal of Research in Pharmacy, 29*, 1350–1366.
12. Parvathaneni, V., Kulkarni, N. S., & Gupta, V. (2020). Current status and perspectives in mucosal drug delivery of nanotherapeutic systems. In *Current Status and Perspectives in Mucosal Drug Delivery of Nanotherapeutic Systems* (pp. 83–106). Springer.
13. Ram, M., Jakhmola, P., Deshmukh, S., & Dhatrak, P. (2024). Review about the application of biocompatible materials in oral cavity drug delivery systems. *Journal of Physics: Conference Series, 2837*, 012034.
14. Jain, D. T. (2024). Smart pills and nanomedicines: The future of drug delivery. In *Smart Pills and Nanomedicines: The Future of Drug Delivery* (pp. 141–158). Iterative Selfypage Developers Pvt.
15. Healy, C. M., & Galvin, S. (2024). Biological therapies and management of oral mucosal disease. *British Dental Journal, 236*, 317–321.

Cite this article:
Dr. Dinesh Venkatesan D. Advances in Topical Drug Delivery for Oral Mucosal Disorders: A Review of Current Strategies. *American Journal of Oral Medicine and Radiology*, 13(1), 2026, 27-34.